ODTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Odyssey Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.10+0.93 (+5.42%)
Close on Oct 19, 2026
- Market cap
- $548.01M
- P/E (TTM)
- –
- Dividend yield
- –
About Odyssey Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Odyssey Therapeutics, Inc. is listed on Nasdaq under the ticker ODTX, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Odyssey Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- 51 Sleeper Street 02210
- Phone
- (212) 841-1000
- Website
- odysseytx.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- ODTX
- Exchange
- Nasdaq
- IPO date
- May 8, 2026
- Shares outstanding
- 48M, Aug 3, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1882782
- CUSIP
- 67613T104
- ISIN
- US67613T1043
- EIN
- 86-3384382
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gary D. Glick | See Remarks, Director | 415,973 |
| Jason Haas | Chief Financial Officer | 62,908 |
| Natalie Dales | See Remarks | 36,880 |
| Anthony W. Opipari | See Remarks | 7,506 |
| Collin M. Todd | See Remarks | – |
| Jolie Siegel | See Remarks | – |
| Dimension Capital II, L.P. | Director | 512,862 |
| Ian F. Smith | Director | 246,100 |
| Timothy P. Walbert | Director | – |
| Jeffrey M. Leiden | Director | 330,540 |
| Nan (LN) Li | Director | 3,333,516 |
| Ourania Tatsis | Director | – |
| Valerie Odegard | Director | – |
| Shelley Chu | Director | 11,111 |
| Aranicki Ksenija Pavletic | Director | – |
| Paulina Hill | Director | – |
| Carolyn Ng | Director | 0 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 8, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| May 5, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |